Pneumagen has announced the publication of phase 2 data showing its antiviral therapy, Neumifil, significantly reduced ...

Enhanced Genomics has appointed Dr Dietrich Stephan as Chair of the Board of Directors. In this role, Dietrich will guide ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

UCB has announced that its phase 3 trial evaluating fenfluramine in CDKL5 deficiency disorder (CDD) achieved its primary and ...

Closed Loop Medicine (CLM) has appointed Kate Woolland as Chief Executive Officer. Previously serving as Chief Operating ...

New data show strong efficacy of CD388 in phase 2b trial Cidara Therapeutics and hVIVO have announced encouraging topline results from a global phase 2b field study evaluating CD388, a drug-Fc ...

Why supporting representative trial participation matters ...

CLEO Systems is also part of the NHS Pathfinder pilot programme with around 200 community pharmacies in England, further ...

A new investigational treatment has shown strong and lasting responses in multiple myeloma patients with extramedullary ...

eXmoor Pharma and Signadori Bio have entered into a partnership aimed at advancing a gene-modified monocyte-derived ...

Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T cells within the tumour microenvironment, with the goal of amplifying ...

These indicators, known as ‘biomarkers’ – which include proteins, chemicals and other molecules that indicate normal or ...